# A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

> **NCT01702493** · PHASE1 · COMPLETED · sponsor: **Sirtris, a GSK Company** · enrollment: 16 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Cap SRT2104
- **DRUG:** Tab SRT2104 slow release
- **DRUG:** Tab SRT2104 intermediate release
- **DRUG:** Tab SRT2104 fast release
- **DRUG:** Selected formulations of SRT2104 from Part 1
- **DRUG:** Selected formulations of SRT2104 from Part 1 single alternative dose

## Key facts

- **NCT ID:** NCT01702493
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-30
- **Primary completion:** 2012-12-05
- **Final completion:** 2012-12-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702493, "A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01702493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*